Nanoscale, antigen encounter-dependent, IL-12 delivery by CAR T cells plus PD-L1 blockade for cancer treatment

BACKGROUND: Chimeric antigen receptor (CAR)-T cell therapies for the treatment of hematological malignancies experienced tremendous progress in the last decade. However, essential limitations need to be addressed to further improve efficacy and reduce toxicity to assure CAR-T cell persistence, traff...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Zhifen, Pietrobon, Violena, Bobbin, Maggie, Stefanson, Ofir, Yang, Jin, Goswami, Angshumala, Alphson, Bennett, Choi, Hana, Magallanes, Khristina, Cai, Qi, Barrett, David, Wang, Bing, Qi, Lei S., Marincola, Francesco M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9976446/
https://www.ncbi.nlm.nih.gov/pubmed/36855120
http://dx.doi.org/10.1186/s12967-023-04014-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9976446/
https://www.ncbi.nlm.nih.gov/pubmed/36855120
http://dx.doi.org/10.1186/s12967-023-04014-9

Ejemplares similares